StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3010% below fair value
$5.70+0.07 (+1.24%)

Close on Nov 17, 2026Market cap $740.90MP/E –Yield –

Cytek Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Cytek Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $37.26M, down 2.3% year over year. For fiscal 2025 it was $36.47M, down 7.4% from the year before. The highest annual figure on record is $44.15M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$36.47M-7.4%
FY2024Dec 31, 2024$39.40M-10.8%
FY2023Dec 31, 2023$44.15M+26.7%
FY2022Dec 31, 2022$34.86M+42.6%
FY2021Dec 31, 2021$24.44M+78.5%
FY2020Dec 31, 2020$13.69M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.74M+10.4%
Q1 FY2026Mar 31, 2026$9.60M-1.2%
Q4 FY2025Dec 31, 2025$8.96M-7.8%
Q3 FY2025Sep 30, 2025$8.96M-9.4%
Q2 FY2025Jun 30, 2025$8.83M-11.7%
Q1 FY2025Mar 31, 2025$9.73M-0.7%
Q4 FY2024Dec 31, 2024$9.72M-10.5%
Q3 FY2024Sep 30, 2024$9.88M-11.5%
Q2 FY2024Jun 30, 2024$10.00M-17.6%
Q1 FY2024Mar 31, 2024$9.80M-1.8%
Q4 FY2023Dec 31, 2023$10.87M+11.5%
Q3 FY2023Sep 30, 2023$11.17M+29.1%
Q2 FY2023Jun 30, 2023$12.14M+43.9%
Q1 FY2023Mar 31, 2023$9.97M+24.3%
Q4 FY2022Dec 31, 2022$9.75M+37.7%
Q3 FY2022Sep 30, 2022$8.65M+42.3%
Q2 FY2022Jun 30, 2022$8.44M+36.2%
Q1 FY2022Mar 31, 2022$8.03M+57.5%
Q4 FY2021Dec 31, 2021$7.08M+61.4%
Q3 FY2021Sep 30, 2021$6.08M+80.0%
Q2 FY2021Jun 30, 2021$6.19M+112.4%
Q1 FY2021Mar 31, 2021$5.09M–
Q4 FY2020Dec 31, 2020$4.39M–
Q3 FY2020Sep 30, 2020$3.38M–
Q2 FY2020Jun 30, 2020$2.92M–

More Cytek Biosciences figures

See a number that looks wrong?